MedTrace Logo

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT07046806 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-07-02

No results posted yet for this study

Summary

To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.

Conditions

  • Hereditary Angioedema (HAE)
  • Angioedema
  • Bradykinin-mediated Angioedema
  • C1 Inhibitor Deficiency

Interventions

DRUG

Deucrictibant XR tablet

Deucrictibant 40 mg XR tablet for prophylaxis

DRUG

Placebo comparator to XR tablet

Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis

DRUG

Deucrictibant 20 mg capsule

Deucrictibant active drug for on-demand treatment of angioedma attacks

DRUG

Placebo comparator to 20 mg capsule

Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks

Sponsors & Collaborators

  • Institute for Asthma and Allergy

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-10
Primary Completion
2026-04-01
Completion
2026-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046806 on ClinicalTrials.gov